We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has asked for more information on the pen injector device used in Sanofi and Zealand Pharma's IGlarLixi combination product for diabetes, and extended its review by three months, hurting its chances to be the first product of its kind on the U.S. market. Read More